Our Pipeline

We place a premium on pursuing programs with strong biological validation, mechanistic diversification, and teams with proprietary capabilities and insights. This framework has resulted in a portfolio consisting of preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases.

Collectively, our portfolio provides enhanced diversification with binary risk removed and asymmetric upside. The portfolio is positioned to withstand the inherent low probability of success associated with drug development of any single asset.

View our Expanded Access Policy for investigational medical products.

Lead Op / IND-Enabling
Phase 1
Phase 2
Phase 3
Your browser is out-of-date!

Update your browser to view this website correctly. Outdated Browser